Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle<sup>4</sup>-<scp>d</scp>-Phe<sup>7</sup>]-α-MSH

Haylett, Ann K.; Nie, Zedong; Brownrigg, M; Taylor, Rachel L.; Rhodes, Lesley E.

doi:10.1111/j.1365-2133.2010.10104.x

Cited by 70 publications

(45 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The chemical structure of the analogue is modified at 2 places, providing a smaller dissociation constant and a stronger binding affinity to the melanocortin 1 receptor (MC1R) and resulting in a longer half-life and therefore longer pharmacologic activity than the biological hormone. 15,23 Similar to ␣-MSH, afamelanotide activates the synthesis, proliferation, and transport of eumelanin within the melanosome. Afamelanotide acts on melanocytes and keratinocytes present in the epidermis, hair follicles, and possibly MC1R, expressing inflammatory cells (neutrophils and lymphocytes), to restore a balanced cytokine environment.…”

Section: Commentmentioning

confidence: 99%

The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo

Grimes

Hamzavi²,

Lebwohl

et al. 2013

JAMA Dermatol

View full text Add to dashboard Cite

Section: Commentmentioning

confidence: 99%

The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo

Grimes

Hamzavi²,

Lebwohl

et al. 2013

JAMA Dermatol

View full text Add to dashboard Cite

“…22 This is especially true in photosensitivity disorders such as EPP 23 and solar urticaria, 24 where the lack of a validated outcome measurement is one of the big obstacles. Studies of orphan medicines frequently do not completely fulfil the rigid requirements of classical study design as pointed out by Buckley, a former member of the Committee for Orphan Medicinal Products of the European Medicines Agency.…”

mentioning

confidence: 99%

Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria

Biolcati

Marchesini²,

Sorge

et al. 2015

Br J Dermatol

View full text Add to dashboard Cite

SummaryBackground In erythropoietic protoporphyria (EPP), an inherited disease of porphyrin-biosynthesis, the accumulation of protoporphyrin in the skin causes severely painful phototoxic reactions. Symptom prevention was impossible until recently when afamelanotide became available. Afamelanotide-induced skin pigmentation has statistically significantly improved light-tolerance, although the clinical significance of the statistical effect was unknown. Objectives To assess clinical effectiveness by recording compliance and safety during prolonged use. Methods We report longitudinal observations of 115 ambulatory patients with EPP, who were treated with a total of 1023 afamelanotide implants over a period of up to 8 years at two porphyria centres; one in Rome, Italy, and the other in Zurich, Switzerland. Results Since the treatment first became available in 2006, the number of patients treated with 16 mg afamelanotide implants rose continuously until June 2014, when 66% of all patients with EPP known to the porphyria centres were treated. Only three patients considered afamelanotide did not meet their expectations for symptom improvement; 23% discontinued the treatment for other, mostly compelling, reasons such as pregnancy or financial restrictions. The quality of life (QoL) scores, measured by an EPP-specific questionnaire, were 31 AE 24% of maximum prior to afamelanotide treatment, rose to 74% after starting afamelanotide and remained at this level during the entire observation period. Only minor adverse events attributable to afamelanotide, predominantly nausea, were recorded. Conclusion Based on the improved QoL scores, high compliance and low discontinuation rates, we conclude that afamelanotide exhibits good clinical effectiveness and good safety in EPP under long-term routine conditions.

show abstract

“…80 Tendo em conta o possível envolvimento de um foto-alergéneo na fisiopatologia da US, a sua remoção através de plasmaferese poderá ser uma opção terapêutica, aplicada com sucesso em alguns casos, particularmente em doentes com teste do soro autólogo irradiado positivo.…”

Section: A B Cunclassified

Fotodermatoses Autoimunes Parte II - Manifestações Clínicas e Terapêutica

Pinheiro

Sousa

Páris

et al. 2018

SPDV

View full text Add to dashboard Cite

RESUMO -As fotodermatoses autoimunes constituem um grupo heterogéneo de dermatoses idiopáticas incluindo cinco entidades clinicamente distintas: erupção polimorfa à luz, prurigo actínico, hydroa vacciniforme, dermite actínica crónica e urticária solar. Algumas destas dermatoses são potencialmente graves e com grande impacto na qualidade de vida dos doentes. Várias medidas de fotoprotecção são suficientes para o tratamento de doentes com formas ligeiras. As opções terapêuticas actuais são limitadas em doentes com doença grave e refractária, reflectindo os mecanismos fisiopatológicos pouco clarificados. Ainda assim, avanços recentes na área da fotoprotecção têm contribuído para um maior sucesso terapêutico. Numa altura em que a área da fotodermatologia tem vindo a perder gradualmente o seu impacto, propomos rever as manifestações clínicas e abordagens terapêuticas actuais das fotodermatoses idiopáticas, entidades raras e que impõem desafios relevantes no seu diagnóstico e tratamento. PALAVRAS-CHAVE - INTRODUÇÃOAs fotodermatoses autoimunes são dermatoses fisiopatologicamente relacionadas entre si, mas com características clínicas distintas.No presente artigo pretendemos rever a apresentação clínica das diferentes entidades, bem como o seu respectivo tratamento.

show abstract

Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle⁴-d-Phe⁷]-α-MSH

Abstract: Melanization following afamelanotide is accompanied by reduction in solar urticaria response across a broad spectrum of wavelengths. Further study is warranted to assess clinical benefit under ambient conditions in summer.

Cited by 70 publications

References 46 publications

The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo

The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo

Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria

Fotodermatoses Autoimunes Parte II - Manifestações Clínicas e Terapêutica

Contact Info

Product

Resources

About

Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-d-Phe7]-α-MSH

Abstract: Melanization following afamelanotide is accompanied by reduction in solar urticaria response across a broad spectrum of wavelengths. Further study is warranted to assess clinical benefit under ambient conditions in summer.

Cited by 70 publications

References 46 publications

The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo

The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo

Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria

Fotodermatoses Autoimunes Parte II - Manifestações Clínicas e Terapêutica

Contact Info

Product

Resources

About

Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle⁴-d-Phe⁷]-α-MSH